Valuation: Rigel Pharmaceuticals, Inc.

Market Cap 845M 724M 675M 620M 1.16B 80.88B 1.19B 8.01B 3.12B 40.53B 3.17B 3.1B 134B P/E 2026 *
14.4x
P/E 2027 * 11.6x
Enterprise Value 845M 724M 675M 620M 1.16B 80.88B 1.19B 8.01B 3.12B 40.53B 3.17B 3.1B 134B EV / Sales 2026 *
2.76x
EV / Sales 2027 * 2.27x
Free-Float
96.65%
Yield 2026 *
-
Yield 2027 * -
1 day+2.09%
1 week+8.03%
Current month+24.97%
1 month+17.02%
3 months+57.59%
6 months+34.27%
Current year+7.40%
1 week 41.37
Extreme 41.3701
47.34
1 month 35.01
Extreme 35.0057
47.34
Current year 24.95
Extreme 24.95
49.1
1 year 24.95
Extreme 24.95
52.24
3 years 7.12
Extreme 7.12
52.24
5 years 6.4
Extreme 6.4
52.24
10 years 6.4
Extreme 6.4
55
Manager TitleAgeSince
Chief Executive Officer 65 21/11/2014
Director of Finance/CFO 63 29/05/2018
Compliance Officer 58 01/12/2022
Director TitleAgeSince
Director/Board Member 71 01/03/1997
Director/Board Member 65 21/11/2014
Chairman 67 01/05/2022
Date Insider Type Main position Quantity % Market Cap.
7/8/26 A Free

Chief Technology Officer

24,400 0.1319%
5/15/26 A Free

Chairman

5,750 0.0311%
2/20/26 A Fiscal year

Director

12,000 0.0661%
Change 5-day change 1-year change 3-year change Capi.($)
+1.81%+8.03%+9.55%+280.17% 845M
+1.24%+6.76%+77.51%+129.06% 1,109B
+1.69%+4.24%+51.68%+62.18% 644B
+1.23%+6.34%+26.63%+76.66% 463B
+0.20%+4.87%+41.87%+46.44% 371B
+0.68%+3.87%+23.64%+41.31% 301B
+0.85%+6.39%+1.20%+14.22% 256B
+1.54%+5.92%+48.70%+68.70% 234B
+0.89%+1.85%-15.71%-52.40% 205B
+2.61%+6.46%+26.83%+93.97% 178B
Average +1.24%+4.32%+29.19%+76.03% 376.19B
Weighted average by Cap. +1.10%+4.53%+44.53%+72.92%

Financials

2026 *2027 *
Net sales 306M 262M 244M 224M 421M 29.25B 429M 2.9B 1.13B 14.66B 1.15B 1.12B 48.54B 373M 319M 298M 273M 514M 35.67B 524M 3.53B 1.38B 17.88B 1.4B 1.37B 59.19B
Net income 61.66M 52.79M 49.25M 45.2M 84.93M 5.9B 86.6M 584M 228M 2.96B 232M 226M 9.79B 81.45M 69.74M 65.06M 59.7M 112M 7.79B 114M 772M 301M 3.91B 306M 299M 12.93B
Net Debt - -
Logo Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.
Employees
173
Date Price Change Volume
21/08/26 $46.20 +2.10% 27,247
20/08/26 $45.25 -3.64% 417,413
19/08/26 $46.96 +7.66% 515,827
18/08/26 $43.62 +2.76% 267,317
17/08/26 $42.45 -0.31% 502,496
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
45.25USD
Average target price
63.00USD
Spread / Average Target
+39.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RIGL Stock